Evidence mapPaperPMID 39590803Full record

ReviewMarine drugs2024

Effects of Marine-Derived Components on Cardiovascular Disease Risk Factors and Gut Microbiota Diversity.

Ingrid Lamminpää, Amedeo Amedei, Cinzia Parolini

Abstract readReview
In one paragraph

Review in Marine drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Cardioprotective and Antioxidant Effects of Marine-DerivedPharmaceuticals (Basel, Switzerland) · 2026
    Article
  2. Review
  3. Frontiers in microbiology · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Macronutrients as Regulators of Intestinal Epithelial Permeability: Where Do We Stand?Comprehensive reviews in food science and food safety · 2025
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ingrid LamminpääDepartment of Clinical and Experimental Medicine, University of Florence, 50134 Florence, Italy.ORCID 0009-0006-1724-8821
Amedeo AmedeiDepartment of Clinical and Experimental Medicine, University of Florence, 50134 Florence, Italy.ORCID 0000-0002-6797-9343
Cinzia ParoliniDepartment of Pharmacological and Biomolecular Sciences, 'Rodolfo Paoletti', Via Balzaretti 9, Università degli Studi di Milano, 20133 Milano, Italy.ORCID 0000-0002-5699-0918

Funding

BANDO DI ATENEO PROGETTI "PROBLEM-DRIVEN"- PROGETTO FONZIE (D.R.1116/2022 prot.202389 0European Union - Next Generation EU, in the context of The National Recovery and Resilience Plan, Investment 1.5 Ecosystems of Innovation, Project Tuscany Health Ecosystem (THE B83C22003920001Progetto Eccellenza 0
6 · The paper itself

Abstract

Cardiovascular diseases (CVDs), which comprise coronary heart disease, hypertension, and stroke, collectively represent the number one cause of death globally. Atherosclerosis is the dominant cause of CVDs, and its risk factors are elevated levels of low-density lipoprotein cholesterol and triglycerides, hypertension, cigarette smoking, obesity, and diabetes mellitus. In addition, diverse evidence highlights the role played by inflammation and clonal haematopoiesis, eventually leading to immunity involvement. The human microbiota project and subsequent studies using next-generation sequencing technology have indicated that thousands of different microbial species are present in the human gut. Disturbances in the gut microbiota (GM) composition, i.e., gut dysbiosis, have been associated with diseases ranging from localised gastrointestinal disorders to metabolic and cardiovascular illnesses. Of note, experimental studies suggested that GM, host immune cells, and marine-derived ingredients work together to ensure intestinal wall integrity. This review discusses current evidence concerning the links among GM, marine-derived ingredients, and human inflammatory disease. In detail, we summarise the impact of fish-derived proteins/peptides and algae components on CVD risk factors and gut microbiome. Furthermore, we describe the interplay among these dietary components, probiotics/prebiotics, and CVDs.

Indexed as

Cardiovascular DiseasesGastrointestinal MicrobiomeAnimalsAquatic OrganismsDysbiosisHeart Disease Risk FactorsHumansPrebioticsProbioticsRisk FactorsPrebioticsatherosclerosis risk factorscardiovascular diseasesfish protein hydrolysatesmarine-derived ingredientsmicrobiotaprobioticsseaweeds

Identifiers

PMID39590803
PMCPMC11595733

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.